SCHEDULE: Janus Henderson Amends Ligand Pharma Stake
Beneficial Ownership Report
Janus Henderson Group plc has filed an Amendment No. 8 to its Schedule 13G, disclosing a 5.5% beneficial ownership stake in Ligand Pharmaceuticals Incorporated as of June 30, 2025.
Summary
- Janus Henderson Group plc, a Jersey-based parent holding company and investment adviser, filed an Amendment No. 8 to its Schedule 13G.
- The filing discloses its beneficial ownership in Ligand Pharmaceuticals Incorporated's Common Stock.
- As of June 30, 2025, Janus Henderson Group plc beneficially owned an aggregate of 1,060,734 shares.
- This aggregate ownership represents 5.5% of Ligand Pharmaceuticals Incorporated's class of Common Stock.
- Janus Henderson Group plc holds shared voting power and shared dispositive power over these 1,060,734 shares.
- Its indirect subsidiary, JHIUS, is deemed to be the beneficial owner of 990,102 shares, representing 5.1% of the class, with shared voting and dispositive power.
- The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 5
Explanation: The filing is a routine beneficial ownership disclosure by an institutional investor, Janus Henderson Group plc, reporting a 5.5% stake in Ligand Pharmaceuticals Incorporated. It does not contain operational or financial performance data for the issuer, thus maintaining a neutral sentiment regarding the company's current state.
Positives
- Janus Henderson Group plc, a significant institutional investment firm, maintains a substantial beneficial ownership stake of 5.5% in Ligand Pharmaceuticals Incorporated, indicating continued investment interest.
Negatives
- NA
Risks
- NA
Future Outlook
NA
Industry Context
This filing is a standard disclosure of a significant ownership stake by an investment firm in a pharmaceutical company. It reflects an investment decision by Janus Henderson within the biotech/pharma sector.
Comparison to Industry Standards
- NA
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
Legal Proceedings
- NA
Related Party Transactions
- NA
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional investor's stake, which can influence market perception and liquidity.
Next Steps
- NA
Key Dates
| Date | Description |
|---|---|
| 2022-12-09 | Date of Power of Attorney execution by Janus Henderson Group plc. |
| 2025-06-30 | Date of event which requires filing of this statement (beneficial ownership reporting date). |
| 2025-08-14 | Date of filing of this Schedule 13G Amendment No. 8. |
Keywords
Ligand Pharmaceuticals, Janus Henderson, Beneficial Ownership, SEC Filing, Schedule 13G, Common Stock, Investment Adviser, Pharmaceutical, Biotech
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.